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Ceramide-activated NAD(P)H oxidase has been reported to
participate in homocysteine (Hcys)-induced abnormal
metabolism of the extracellular matrix (ECM) in rat
glomerular mesangial cells. However, it remains unknown
whether this ceramide–redox signaling pathway contributes
to glomerular injury induced by hyperhomocysteinemia
(hHcys) in vivo. The present study was designed to address
this question, defining the role of ceramide and activated
NAD(P)H oxidase in the development of hHcys-induced
glomerular injury. Uninephrectomized Sprague–Dawley rats
were fed a folate-free diet for 8 weeks to produce hHcys and
the de novo ceramide synthesis inhibitor myriocin or the
NAD(P)H oxidase inhibitor apocynin was administrated. Rats
with folate-free diet significantly increased plasma Hcys
levels, renal ceramide levels, and NAD(P)H oxidase activity
accompanied by marked glomerular injury. Treatment of rats
with myriocin significantly reduced ceramide levels and
improved glomerular injury, as shown by decreased urinary
albumin excretion and reduced glomerular damage index.
ECM components changed towards to normal levels with
decreased tissue inhibitor of metalloproteinase-1 and
increased matrix metalloproteinase-1 activity. NAD(P)H
oxidase activity and Rac GTPase activity were reduced by 69
and 66%, respectively. In rats treated with apocynin, similar
beneficial effects in protecting glomeruli from hHcys-induced
injury were observed. These results support the view that
de novo ceramide production is involved in Hcys-induced
NAD(P)H oxidase activity in the kidney of hHcys rats and
indicate the important role of ceramide-mediated redox
signaling in hHcys-induced glomerular injury in rats.
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Hyperhomocysteinemia (hHcys) is emerging as a critical
pathogenic factor in the progression of end-stage renal
disease and in the development of cardiovascular complica-
tions related to end-stage renal disease.1–6 We have demon-
strated that chronic elevations of plasma Hcys levels even for
just 2 weeks induced proteinuria, mesangial (MG) expansion
and glomerulosclerosis, without elevation of arterial blood
pressure in uninephrotemized rats, indicating that increased
plasma Hcys levels importantly contribute to the develop-
ment of glomerular disease independent of hypertension.7
Despite substantial evidence indicating the association of
hHcys and end-stage renal disease, the mechanisms by which
Hcys promotes the development of glomerulosclerosis
remains unknown.
Given the similarity of pathological changes between
Hcys-induced glomerular injury and Hcys-induced arterial
damages such as endothelial injury, cell proliferation,
increased matrix formation and aggregated protoglycan,8–10
the increase in plasma Hcys may also play a crucial role in
initiating and facilitating glomerular injury in hypertensive
and end-stage renal disease individuals. Moreover, impaired
renal function will lead to a further increase in plasma Hcys,
which, in turn, exaggerates the progression of glomerular
injury, resulting in a vicious cycle and, consequently, in
glomerulosclerosis. These Hcys involved a variety of cellular,
biochemical, and molecular events are importantly related to
local oxidative stress.11–13 Therefore, the oxidative stress-medi-
ated pathogenic mechanism may contribute to Hcys-induced
glomerular injury.
Recently, we have demonstrated that Hcys acutely
increases superoxide (O2
K
) production via NAD(P)H oxidase
and thereby stimulates the formation of tissue inhibitor of
metalloproteinase-1 (TIMP-1) in rat MG cells, ultimately
resulting in the deposition of collagen.14 We further
demonstrated that Hcys increased de novo ceramide synthesis
in rat MG cells. This increased ceramide activated Rac
GTPase and enhanced NAD(P)H oxidase activity.15 In
previous studies, sphingolipids, in particular, ceramide, play
a very important role in cell membrane formation, signal
transduction, and plasma lipoprotein metabolisms, all of
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which have an impact on the development of atherosclero-
sis.16–18 In addition, ceramide is considered as a critical
signaling molecule mediating the activation of NAD(P)H
oxidase in different cells.15,19 Therefore, we hypothesized that
ceramide-induced NAD(P)H oxidase activity may impor-
tantly participate in the development of hHcys-induced
glomerular injury. In the present study, we utilized myriocin
to inhibit serine palmitoyl-coenzyme A transferase, the key
enzyme for de novo ceramide synthesis, and examined the
role of endogenous-produced ceramide in the development
of Hcys-induced glomerulosclerosis in an experimental
hHcys animal model and explored related mechanisms. We
also treated hHcys rats with an NAD(P)H oxidase inhibitor,
apocynin, to observe its beneficial actions on hHcys-induced
glomerular injury. Our results provided direct evidence,
indicating that increased plasma Hcys stimulates ceramide
production and NAD(P)H oxidase activity in the kidney of
hHcys rats. We further demonstrated that ceramide-activated
NAD(P)H oxidase promotes the formation of TIMP-1 and
decrease matrix metalloproteinase-1 (MMP-1) activity,
ultimately leading to glomerulosclerosis in hHcys rats.
RESULTS
Plasma total Hcys levels significantly increased in rats with
folate-free diet
High-pressure liquid chromatography (HPLC) chromato-
grams of ABD-F-derivatized standards of several thiol
compounds are presented in Figure 1a. Standard thiol
solution contains cysteine, Hcys, glutathione, cysteinylgly-
cine, and the internal standard TGA. Hcys had a retention
time of 7.4 min, clearly separated from other thiol com-
pounds. In uninephrectomized Sprague–Dawley rats, an 8
week-folate-free diet significantly increased plasma total Hcys
levels. Neither apocynin nor myriocin had effect on the
increase of Hcys levels induced by a folate-free diet. The
results were summarized in Figure 1b. Additionally, two
groups of rats were continuously administrated myriocin or
apocynin with a normal diet had no significant change in
Hcys levels, suggesting that either apocynin or myriocin only
does not alter Hcys metabolism.
Effect of myriocin and apocynin on glomerular damage
induced by hHcys
To determine whether the ceramide–redox pathway con-
tributes to Hcys-induced glomerular injury, we examined
urinary protein, albumin excretion, and glomerular morpho-
logy in rats fed a folate-free diet. In parallel to increase in
plasma total Hcys, both urinary protein and urinary albumin
were significantly increased in rats fed a folate-free diet with
more dramatic increase in urinary protein (Figure 2).
Morphological analysis showed that glomerular extracel-
lular matrix (ECM) markedly increased and the glomerular
mesangium was expanded with hypercellularity, capillary
collapse, and fibrous deposition in the glomerulus in hHcys
rats (Figure 3a). The semiquantitative injury score of
glomeruli with the average glomerular damage index was
substantially higher in rats fed a folate-free diet than in rats
fed a normal diet (Figure 3b).
However, treatment of hHcys rats with myriocin or
apocynin markedly reduced urinary protein excretion,
albumin excretion, and glomerular damage index increase
induced by hHcys. Myriocin or apocynin alone had no effects
on the urinary protein and albumin excretion in rats with a
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Figure 1 | Fluorescent HPLC chromatograms of Hcys and other
thiols from standard solutions and plasma. (a) HPLC chromato-
grams showing standards (STD) containing 40mM cysteine (Cys), 20mM
Hcys and glutathione (GSH), 5 mM cysteinylglycin (Cysgly), and internal
standard, 50mM TGA and Hcys, and other thiols in the plasma from
Sprague–Dawley (SD) rat with normal diet or folate-free diet (FF).
(b) Average plasma total homocysteine concentrations in different
groups of rats on a normal diet with or without myriocin (Myr) and
apocynin (Apo) treatments or a folate-free diet with or without Myr
and Apo treatments (n¼ 7). *Po0.05 compared with control.
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regular chow. Based on these results, we conclude that
inhibition of de novo ceramide synthesis or blockade of
NAD(P)H oxidase does not have effects on glomerular
structure and function in rats on a normal diet. In the
following mechanism studies, therefore, only four groups of
experiments are presented that include normal diet or folate-
free diet with or without myriocin or apocynin.
Effects of myriocin and apocynin on Hcys-increased
expression of TIMP-1 mRNA and protein levels
By real-time reverse transcription-polymerase chain reaction
and Western blot analysis, TIMP-1 mRNA and protein levels
in the renal cortex from rats with hHcys were increased by
61.0 and 47.5%, respectively (Figure 4a and b). Both
myriocin and apocynin attenuated Hcys-induced increase.
The results were summarized in Figure 4c.
Restoration of Hcys-reduced MMP-1 activity by myriocin and
apocynin treatments
To examine whether the regulation of MMP-1 activity, an
important form of MMPs in the kidney, is associated with
ceramide–redox signaling pathway in hHcys rats, MMP-1
activity was measured and the results are summarized in
Figure 5. MMP-1 activity in the renal cortex of hHcys rats
was markedly reduced to 54% of control group, and myriocin
and apocynin treatments can partially restore Hcys-reduced
MMP-1 activity to 85 and 81%, respectively.
Quantitation of ceramide levels in the renal cortex
of hHcys rats
Using liquid chromatography/mass spectrometry analysis, we
identified and quantified six different ceramides (C14, C16,
C18, C20, C22, C24). In these renal cortical samples, C16 and
C24 ceramides are the most abundant species (98% of total
ceramides). As summarized in Figure 6, in hHcys rats renal
cortical ceramide levels significantly increased by 58%. When
these rats were treated with myriocin, increases in renal
cortical ceramide levels were attenuated by 98%. Moreover,
there was no significant decrease in ceramide levels in the
apocynin-treated hHcys rats. On a regular chow, rats
receiving apocynin had no changes in ceramide levels in
their kidneys, but rats receiving myriocin exhibited a
decreased ceramide level of 22% in their kidneys as compared
with control rats (Figure 6).
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Figure 2 | Measurement of urinary protein and urinary albumin
excretion. (a) Urinary protein and (b) urinary albumin excretion in six
different groups of rats fed a normal diet or folate-free diet with
or without myriocin and apocynin treatments (n¼ 7). *Po0.05
compared with control. #Po0.05 compared with the values
obtained from vehicle-treated hHcys rats.
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Figure 3 | Morphological features of the glomeruli from different
groups of rats including a normal diet or folate-free diet with
or without myriocin and apocynin treatments (n¼ 7).
(a) Photomicrographs (original magnification,  250) showing
typical glomerular structure in control and different treatment
groups of rats. (b) Semiquantitative score of glomerular damage
index (n¼ 7). *Po0.05 compared with control. #Po0.05 compared
with the values obtained from vehicle-treated hHcys rats.
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Blockade of enhanced NAD(P)H oxidase activity in hHcys rats
by inhibition of de novo ceramide synthesis
The activity of NAD(P)H oxidase was determined by
fluorescence spectrometric assay. Summarized data showed
that NAD(P)H oxidase activity increased by 61% in the renal
cortex of rats fed a folate-free diet compared with control
rats. Administration of apocynin and myriocin markedly
attenuated hHcys-induced NAD(P)H oxidase activity by 69
and 55% (Figure 7).
Expression of NAD(P)H oxidase subunits in the renal cortex
To explore the mechanism by which myriocin attenuate
Hcys-induced NAD(P)H oxidase activity in hHcys rats, we
examined expression levels of NAD(P)H oxidase subunits in
the renal cortex of these treated rats. The representative
subunits p47phox, p67phox, non-phagocytic NAD(P)H oxidase
(NOX)-2, and NOX-4 of NAD(P)H oxidase were detected by
Western blot analysis. As shown in Figure 8a, expression of
these subunits in the renal cortex was not significantly
changed. These results are summarized in Figure 8b.
Rac GTPase activation is involved in ceramide–redox
signaling pathway induced by hHcys
As documented in Figure 9a, hHcys produced a significant
increase in GTP-bound Rac levels in the renal cortex of hHcys
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Figure 4 | TIMP-1 mRNA and protein expression levels in the renal
cortex from different group of rats on a normal diet, folate-free
diet with or without myriocin and apocynin treatment (n¼ 7).
(a) Summarized data showing TIMP-1 mRNA levels in the renal cortex
from these rats. (b) Immunoblot for TIMP-1 in the renal cortex from
these rats. (c) Summarized data showing changes in TIMP-1 protein
levels in the renal cortex from these groups of rats. *Po0.05
compared with control. #Po0.05 compared with the values obtained
from vehicle-treated hHcys rats.
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Figure 5 | Effects of de novo ceramide synthesis inhibitor
myriocin and NAD(P)H oxidase inhibitor apocynin on the MMP-1
activity in the renal cortex from these hHcys rats (n¼ 7). *Po0.05
compared with control. #Po0.05 compared with the values obtained
from vehicle-treated hHcys rats.
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Figure 6 | Effects of de novo ceramide synthesis inhibitor
myriocin and NAD(P)H oxidase inhibitor apocynin on ceramide
production in the renal cortex of hHcys rats (n¼ 6). Values are
mean7s.e. from seven samples each group. *Po0.05 compared
with control. #Po0.05 compared with the values obtained from
vehicle-treated hHcys rats.
Et
h-
D
N
A 
flu
or
es
ce
nc
e 
in
cr
ea
se
 
 
 
 
 
 
 
 
 
 
 
 
( %
 vs
 co
ntr
ol)
60
80
100
120
140
160
180
*
# #
Control FF FF+Apo FF+Myr
Figure 7 | NAD(P)H oxidase activity in the renal cortex from
different groups of rats on a normal diet or folate-free diet with
or without myriocin and apocynin treatments (n¼ 7). Summarized
data showing the effect of Hcys and inhibitors on NAD(P)H-
dependent activity in these renal cortex. Data were presented as
percent increases in ethidium fluorescence compared to control.
*Po0.05 compared with control. #Po0.05 compared with the values
obtained from vehicle-treated hHcys rats.
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rats compared with the control group. However, adminis-
tration of myriocin significantly blocked the Hcys-induced
increase in activated Rac levels. The results are summarized in
Figure 9b.
DISCUSSION
Recently, we have demonstrated that chronic elevations
of plasma Hcys induces glomerulosclerosis and indicated
that increased Hcys levels play an important role in the
development of glomerulosclerosis. In in vitro experi-
ments, Hcys was found to increase O2
K
production
via stimulation of de novo ceramide synthesis and subsequent
enhancement of Rac GTPase activity, which in turn
stimulates the formation of TIMP-1 in MG cells,
consequently producing the deposition of collagen.14,15
However, it remains unknown whether this ceramide–redox
signaling pathway does contribute to the development of
glomerulosclerosis associated with hHcys in vivo. In the
present study, we performed a series of experiments to
investigate the role of this ceramide–redox signaling pathway
in the hyperhomocysteinemic glomerular injury in an
experimental hHcys animal model produced by feeding rats
with a folate-free diet.
hHcys– associated with folate-free diet induced significant
glomerular injury
It is well known that Hcys is an intermediate metabolite of
methionine metabolism and is metabolized by two pathways:
namely, the re-methylation pathway that regenerates methio-
nine by cofactors folate and vitamin B12, and the trans-
sulfuration pathway that degrades Hcys into cysteine and
then taurine by vitamin B6 and other relative coenzymes.
Therefore, two major experimental models to produce hHcys
are widely used.20–22 One is to use methionine-rich diet,
whereby methionine can be metabolized to produce Hcys,
and another is to use folate-free diet. Considering the
treatment of hHcys in clinical studies by administration folic
acid and other vitamin supplementation to reduce Hcys
levels and some concern about possible nonspecific effects of
methionine in producing hHcys, the present study employed
an animal model to induce hHcys by dietary folate
restriction. Our results showed that an 8-week folate-free
diet significantly increased plasma Hcys. In these rats,
remarkable glomerular damage or sclerosis was observed, as
shown by increased injury score of glomeruli and enhanced
urinary protein and albumin excretion. In these rats, urinary
protein excretion increased much higher than albumin
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Figure 8 | Expression of NAD(P)H oxidase subunits in the renal
cortex from different groups of rats on a normal diet or
folate-free diet with or without myriocin and apocynin
treatment (n¼ 7). (a) Immunoblot for p47phox, p67phox, and
NOX-2 (gp91phox) and NOX-4 in the homogenates from the renal
cortex of these rats. (b) Summarized data showing changes in
p47phox, p67phox, NOX-2 (gp91phox), and NOX-4 in the renal cortex
from different groups of rats.
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Figure 9 | Rac GTPase activity in the renal cortex from different
groups of rats fed on anormal diet or folate-free diet with or
without myriocin and apocynin treatment (n¼ 7). (a) Immunoblot
for Rac GTPase activity and total Rac GTPase expression levels.
(b) Summarized data showing changes in Rac GTPase activity and
total RaC GTPase expression in renal cortex. *Po0.05 compared
with control. #Po0.05 compared with the values obtained from
vehicle-treated hHcys rats.
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excretion compared with those of control rats. It is possible
that in addition to filtered albumin, some other proteins owing
to injury of other tissues may enter into urine, suggesting that
renal tissue degeneration may occur in hHcys rats.
It is well known that glomerular accumulation of the ECM
is the common pathologic feature of glomerular injury, and
alterations in the synthesis and degradation of the ECM are
importantly involved in the accumulation of the ECM in the
glomerular. Recent studies have demonstrated the pathologic
role of matrix-degrading MMPs and their inhibitor TIMPs in
glomerular injury.23 MMPs can break down collagens and
thereby importantly regulate the amount of the ECM.24,25 It
has been reported that TIMP-1 plays a key role in the
regulation of the ECM accumulation in glomerular injury or
sclerotic diseases. Excessive TIMP-1 can markedly reduce the
MMPs activity.26,27 It is known that MMP-1 is an important
proteolytic enzyme that degrades collagens.27,28 In the
present study, it was found that both TIMP-1 mRNA
expression and protein levels in the renal cortex from hHcys
rats were significantly increased and fluorescence resonance
energy transfer (FRET) assay demonstrated that the MMP-1
activity was markedly reduced. These results indicated that
hHcys associated with folate-free diet induced an abnorm-
ality of the ECM in the glomeruli, which may ultimately lead
to severe significant glomerular injury.
Role of de novo ceramide synthesis in hHcys-induced
glomerular injury
In hHcys rats fed a folate-free diet, we tested whether
ceramide is involved in hHcys-induced NAD(P)H oxidase
activity and consequent glomerular injury. Ceramide, a
potent regulator of cell proliferation, activation, and
apoptosis, plays an important role in lipoprotein aggregation
and may promote foam cell formation in atherosclerosis.29 It
has been implicated in the detrimental actions of many
different injury factors in different cells and tissues.18,29,30
Recent reports have shown that serine palmitoyl-coenzyme A
transferase inhibition by myriocin leads to a reduction of
plasma sphingomyelin, ceramide production, and athero-
sclerosis in apolipoprotein E-knockout mice.31,32 More
recently, we reported that de novo ceramide synthesis
contributes to Hcys-induced activation of NAD(P)H oxidase
activity in MG cells.15 In this regard, the possible pathological
relevance of ceramide to glomerular injury induced by Hcys
was proposed. The present study explored this possibility in
experimental hHcys rats. We utilized myriocin to inhibit the
first step of de novo ceramide synthesis and to determine the
impact of serine palmitoyl-coenzyme A transferase inhibition
on lipid metabolism and glomerulosclerosis development in
hHcys rats. It was found that renal cortical ceramide levels in
hHcys rats significantly increased and that treatment of rats
with myriocin markedly reduced ceramide production in the
kidneys of these rats. Meanwhile, glomerular injury in
myriocin-treated rats was markedly improved as shown by
reduced urinary or albuminuria and decreased glomerular
damage index. Correspondingly, ECM components changed
towards to normal level with decreased TIMP-1 and
increased MMP-1 activity. These results provide direct
evidence indicating the important role of spingolipids,
especially ceramide in hHcys-induced glomerular injury in
rats. It should be noted that myriocin may have nonspecific
effects in the protection of glomeruli from injury associated
with hHcys. However, several lines of evidence support that
at the dose used with 8-week treatment myriocin may
primarily work on de novo ceramide synthesis. First, liquid
chromatography/mass spectrometry analysis demonstrated
that myriocin significantly inhibited ceramide production in
rats with hHcys. Second, in the rats treated with myriocin,
increase in NADPH oxidase activity by hHcys was markedly
blocked. Based on our previous studies,19 it is ceramide,
rather than other sphingolipid that stimulates NADPH
oxidase. This further supports that the action of myriocin
is through inhibition of ceramide production. Third, recent
studies have indicated that immunomodulation is not
responsible for myriocin-induced inhibition of atherogenesis
in apolipoprotein E-knockout mice.32 In addition, although
immune cell dysfunction may play some roles in the
development of glomerular sclerosis, it is well accepted that
this immunopathogenic effect may not be a major mechan-
ism responsible for the development of glomerular sclerosis.
Increased NAD(P)H oxidase activity contributes to
hHcys-induced glomerular injury
It is well known that reactive oxygen species decisively
contributes to cellular signaling, affecting almost all aspects
of cellular function including gene expression, proliferation,
migration, cell death, and sclerosis.33,34 Although multiple
enzymes contribute to oxidative stress in different tissues or
cells, recent studies have been demonstrated that NAD(P)H
oxidase is a major enzyme to produced O2
K
in the kidney
under physiological conditions.35 NAD(P)H oxidase was
initially characterized in neutrophils including membrane
subunits p22phox and gp91phox and cytoplasmic subunits
p47phox, p40phox, p67phox, and Rac GTPase.36,37 In the past few
years, a family of gp91phox-like proteins, termed the NOX
proteins, has also been discovered which includes NOX1,
NOX2 (gp91phox), NOX3, NOX4, and NOX5. NOX4 is
mainly expressed in the kidney.38 In recent studies, we have
demonstrated that Hcys increases NAD(P)H oxidase-induced
O2
K
and thereby stimulates TIMP-1 in renal MG cells,
ultimately resulting in the deposition of collagen. The present
study demonstrated in vivo that NAD(P)H oxidase activity
significantly increased in the renal cortex of rats fed a folate-
free diet. When these hHcys rats were treated with an
NAD(P)H oxidase inhibitor, apocynin, significant beneficial
effects to improve various hHcys-induced biochemical or
morphological alternations in the glomeruli were observed
including decreased urinary protein excretion, improved
glomerular damage, and increased MMP-1 activity. Interest-
ingly, analysis of NADPH oxidase activity showed that Hcys-
induces increase in NADPH activity was also markedly
attenuated in the presence of myriocin, a de novo ceramide
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synthesis inhibitor. These results provide direct evidence
supporting the view that O2
K
production is associated with
NADPH oxidase in hHcys rats.
To explore the mechanisms by which Hcys activates
NAD(P)H oxidase in hHcys rats, we first examined expression
level of NAD(P)H oxidase subunits. Western blot analysis
showed that the amount of NAD(P)H oxidase subunits in the
renal cortex had no change, no matter whether the rats were
treated by myriocin or apocynin, suggesting that increased
NAD(P)H oxidase activity is not through increased protein
expression levels. Then, we tested whether Rac GTPase, a
critical regulator, contributes to increased NAD(P)H oxidase
activity in hHcys rats. It was reported that Rac-GTP interacts
with the N-terminal of p67phox for the assembly of NAD(P)H
oxidase subunits to activate this enzyme.39,40 In our recent
studies, ceramide was found to increase via its de novo
synthesis by Hcys treatment in rat MG cells. This increased
ceramide-activated Rac GTPase and enhanced NAD(P)H
oxidase activity. The present study indicated that Rac activity
was increased by 88.3% in the kidney of hHcys rats. When
myriocin was administrated, Hcys-induced increase in Rac
GTPase activity was markedly reduced, but apocynin had no
effect. These results further support the view that de novo
ceramide production is involved in Hcys-induced NAD(P)H
oxidase activity by activation of Rac GTPase in the kidney of
hHcys rats.
In summary, the present study demonstrates that
ceramide-activated NAD(P)H oxidase is responsible for
glomerular injury associated with hHcys in vivo and that
activation of NAD(P)H oxidase is attributed to increased
Rac-GTPase activity in the kidney of the hHcys rats. These
results suggest a new pathogenic pathway contributing to
glomerular injury associated with hHcys, which may direct
toward the development of new therapy of end-stage renal
diseases related to hHcys.
MATERIALS AND METHODS
Animals
Experiments were performed using Sprague–Dawley rats (200 g, 6
weeks old) purchased from Harlan Inc. (Madison, WI, USA). To
speed up the damaging effect of Hcys on the glomeruli, the rats were
uninephrectomized. After a 1-week recovery period from unine-
phrectomy, the rats were maintained on a regular chow or a folate-
free diet, which was purchased from Dyets Inc. (Bethlehem, PA,
USA) for 8 weeks. In additional groups, de novo ceramide synthesis
inhibitor, myriocin (0.3 mg/kg/day, intraperitoneally), or NAD(P)H
oxidase inhibitor, apocynin (15 mg/kg/day in drinking water), was
continuously administrated throughout the period feeding a normal
diet or folate-free diet. Myriocin and apocynin doses were chosen
according to recent reports31,32 and our previous dose-dependent
experiments. All protocols were approved by Institutional Animal
Care and Use Committee of both Medical College of Wisconsin and
Virginia Commonwealth University. During recording days, blood
and 24-h urine samples were collected. Plasma total Hcys was
measured by fluorescence HPLC analysis as described.41 Urinary
protein concentration was determined by BCA assay kit (Bio-Rad,
Hercules, CA, USA). Urinary albumin excretion was measured using
a rat albumin enzyme-linked immunosorbent assay quantitation kit
(Bethyl Laboratories, Montgomery, TX, USA).
NAD(P)H oxidase assay
A dihydroethidium-based fluorescence spectrometric assay was used
to assess O2
K
production from NAD(P)H oxidase.14,15
Dihydroethidium is oxidized specifically by O2
K
to yield
ethidium, which binds DNA and has fluorescence at
excitation/emission of 480/610 nm. Briefly, 20 mg proteins
were incubated with 100 mM dihydroethidium and 0.5 mg/ml
salmon test DNA (binds ethidium to amplify fluorescence
signal) in 200 ml phosphate-buffered saline. NADPH (1 mM)
was added immediately before recording ethidium fluores-
cence by a fluorescence microplate reader (FLX800, Bio-Tek,
Winooski, VT, USA). The ethidium fluorescence increase was
used to represent NAD(P)H oxidase activity.
Western blot analysis
Western blotting was performed as described.14,15 Briefly, 20mg
proteins were subjected to SDS-polyacrylamide gel electrophoresis,
transferred onto a nitrocellulose membrane, and blocked. The
membrane was probed with primary monoclonal antibodies: anti-
p47phox, anti-p67phox, anti-gp91phox (1:1000 dilution; BD Transduc-
tion Laboratories, Lexington, KY, USA), anti-TIMP-1 (1:1000
dilution; R&D systems, Minneapolis, MN, USA), or anti-NOX-4
(1:500 dilution, Santa Cruz Biotech, Santa Cruz, CA, USA),
overnight at 41C followed by incubation with horseradish
peroxidase-labeled anti-mouse immunoglobulin G or anti-goat
immunoglobulin G. The immunoreactive bands were detected by
chemiluminescence methods and visualized on Kodak Omat film.
Rac GTPase activation assay
A specific pull-down experiment was performed to determine Rac
GTPase activation using an Rac activation assay kit (Upstate, Lake
Placid, NY, USA) as described.15 Briefly, the renal cortex tissue was
lysed in Mg2þ lysis buffer. After precleaned by glutathione agarose,
the pull-down proteins (200 mg/sample) were incubated with 10mg
of PAK-1 PBD (glutathione S-transferase fusion protein, corre-
sponding to p21-binding domain (PBD, residues of 67–150) of
human PAK-1) agarose for one hour at 41C to bind Rac-GTP. Then,
the pelleted beads were washed three times with Mg2þ lysis buffer,
resuspended in 25 ml of 2 Laemmli reducing sample buffer, and
boiled for 5 min. The sample mixtures were then loaded onto SDS-
polyacrylamide gel electrophoresis gels. The bound active GTP-Rac
was analyzed by Western blotting using anti-Rac monoclonal
antibody.
RNA extraction and real-time reverse transcription-
polymerase chain reaction of TIMP-1
Total RNA was isolated from renal cortex using TRIzol reagent
(GIBCO, Life Technologies, Carlsbad, CA, USA) according to the
protocol described by the manufacturer. The mRNA levels for
TIMP-1 were analyzed by real-time quantitative reverse transcrip-
tion-polymerase chain reaction using a Bio-Rad iCycler system (Bio-
Rad, Hercules, CA, USA) according to the protocol described by the
manufacturer. The mRNA level of TIMP-1 was normalized to the
18S mRNA. The specific primers for TIMP-1 based on the core
sequence of rat TIMP-1 cDNA (Accession number NM-003254)
were 50-CCA GAA ATC ATC GAG ACC AC-30 (forward) and
50-CGG AAA CCT GTG GCA TTT-30 (reverse).
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FRET assay for MMP-1 activity measurement
MMP-1 activity was measured using EnzoLyteTM 520 MMP-1 assay
kit from AnaSpec Inc. (San Jose, CA, USA). This kit uses a 5-FAM
(fluorophore)- and QXL520TM (quencher)-labeled FRET peptide
substrate for continuous measurement of the enzyme activities. In
an intact FRET peptide, the fluorescence of 5-FAM is quenched by
QXL520TM. Upon the cleavage of the FRET peptide by MMP-1, the
fluorescence of 5-FAM is recovered, and can be continuously
monitored at excitation/emission (490/520 nm). MMP-1 activity
was measured according to the protocol described by the
manufacturer. The change of enzyme activity of MMP-1 was
presented as percent change in relative fluorescence unit vs control.
Liquid chromatography–electrospray ionization tandem–-
mass spectrometry for quantitation of ceramide
Separation, identification and quantitation of ceramide in renal
cortex were performed by liquid chromatography/mass spectro-
metry. The HPLC is from HP 1100 series equipped with a binary
pump, a vacuum degasser, a thermostated column compartment,
and an autosampler (Agilent Technologies, Waldbronn, Germany).
The HPLC separations were performed at 701C on an RP C18
Nucleosil AB column (5mm, 70 mm 2 mm i.d.) from Macherey
Nagel (Du¨ren, Germany). The mobile phase was a gradient mixture
formed as described.42 The tissue lipids were extracted according to
previous studies.15,42 To avoid any loss of lipids, the whole
procedure was performed in siliconized glassware. Mass spectro-
metry detection was carried out using an Ultima triple quadrupole
instrument (Micromass, Manchester, UK) operating under Mass-
Lynx 3.5 and configured with a Z-spray electrospray ionization
source. Source conditions were as described previously.42
Morphological examination
The fixed kidneys were paraffin-embedded, and sections were
prepared and stained with periodic acid-Schiff stain. Glomeruli were
evaluated (scored from 0 to 4) on the basis of the degree of
glomerulosclerosis and MG matrix expansion as we described
before.7
Statistical analysis
Data are presented as mean7s.e.m. Significant differences between
and within multiple groups were examined using analysis of
variance for repeated measures, followed by Duncan’s multiple-
range test. Student’s t-test was used to evaluate the significant
differences between two groups of observations. Po0.05 was
considered statistically significant.
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